PHAT therapy expansion targets $2B+ peak sales on rising physician adoption
A gastroesophageal reflux therapy is driving rapid revenue growth, with peak sales potential exceeding $2B via expansion into daily and as-needed use. Physician adoption is rising on streamlined access, supported by pipeline and exclusivity extensions.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.